New pathogens for respiratory infections

Current Opinion in Pulmonary Medicine

Volumn 2, Issue 3, 1996, Pages 174-180

  Cosentini, Roberto ^a   Blasi, Francesco ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

AGRICULTURE; ANIMAL; ANTIBIOTIC RESISTANCE; ASTHMA; BACTERIAL PNEUMONIA; CAPILLARY LEAK SYNDROME; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNICABLE DISEASE; HANTAVIRUS; HANTAVIRUS PULMONARY SYNDROME; HOSPITAL SERVICE; HUMAN; MICROBIOLOGY; MORTALITY; MULTIPLE ORGAN FAILURE; PENICILLIN RESISTANCE; PEROMYSCUS; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VIROLOGY;

AGRICULTURE; ANIMALS; ANTI-BACTERIAL AGENTS; ASTHMA; CAPILLARY LEAK SYNDROME; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; HANTAVIRUS; HANTAVIRUS PULMONARY SYNDROME; HOUSEKEEPING; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MULTIPLE ORGAN FAILURE; PENICILLIN RESISTANCE; PEROMYSCUS; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, BACTERIAL; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE;

EID: 0030132798     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199605000-00003     Document Type: Article

References (69)

1. Hughes JM, Peters JC, Cohen ML, Mahy BWJ: Hantavirus pulmonary syndrome: an emerging infectious disease. Science 1993, 262:850-851.
2. Centers for Disease Control: Update: hantavirus disease-United States, 1993. MMWR CDC Surveill Summ 1993, 42:612-614.
3. Centers for Disease Control: Hantavirus pulmonary syndrome: Virginia. MMWR CDC Surveill Summ 1994, 43:876-877.
4. Centers for Disease Control: Newly identified hantavirus: Florida. Morb Mortal Wkly Rep 1994, 43:99-105.
5. Butler JC, Peters CJ: Hantaviruses and hantavirus pulmonary syndrome. Clin Infect Dis 1994, 19:387-395.
6. Elliot Lh, Ksiazek TG, Rollin PE, Spiropoulou CF, Morzunov S, Monroe M, Goldsmith CS, Humphrey CD, Zaki RS, Krebs JW, et al.: Isolation of the causative agent of hantavirus pulmonary syndrome. Am J Trop Med Hyg 1994, 51:102-108.
7. Centers for Disease Control: Hantavirus pulmonary syndrome: northeastern United States, 1994. MMWR CDC Surveill Summ 1994, 43:548-549; 555-556.
8. Kahn AS, Ksiazek TG, Zaki SR, Nichol ST, Rollin PE, Peters CJ, Khabbaz RF, Cheek JE, Shereley LA, McDonough S, et al.: Fatal hantavirus pulmonary syndrome in an adolescent. Pediatrics 1995, 95:276-280. Interesting case report of one of the few pediatric cases of HPS. Clinical course, and particularly the unusual vestibular symptoms, risk factors, and pediatric hantavirus diseases are discussed.
9. Turell MJ, Korch GW, Rossi CA, Sesline D, Enge BA, Dondero DV, Jay M, Ludwig GV, Li D, Schmaljohn CS, et al.: Short report: prevalence of hantavirus infection in rodents associated with two fatal human infections in California. Am J Trop Med Hyg 1995, 52:180-182. Evaluates in detail the seroprevalence of hantavirus infection in rodents captured in the area where two fatal HPS cases occurred. Results suggest that Peromyscus mice, particularly P. maniculatus, may be the main reservoir of the virus in California, confirming previous data from New Mexico and Arizona.
10. Zeitz PS, Butler JC, Cheek JE, Samuel MC, Childs JE, Shands LA, Turner RE, Voorhees RE, Sarisky J, Rollin PE, et al.: A case-control study of hantavirus pulmonary syndrome during an outbreak in the southwestern United States. J Infect Dis 1995, 171:864-870. An outstanding investigation of risk factors for HPS. The authors compared 17 case-patients with three control groups (case-patients households, near- and farhouseholds). Significant risk factors were peridomestic cleaning, agricultural activities, and an increased number of small rodents in the household.
11. Duchin JS, Koster FT, Peters CJ, Simpson GL, Tempest B, Zaki SR, Ksiazek TG, Rollin PE, Nichol S, Umland ET, et al.: Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. N Engl J Med 1994, 330:949-955.
12. Zaki SR, Greer PW, Coffield LM, Goldsmith CS, Nolte KB, Foukar K, Feddersen RM, Zumwalt RE, Miller GL, Khan AS, et al.: Hantavirus pulmonary syndrome: pathogenesis of an emerging infectious disease. Am J Pathol 1995, 146:552-579. The authors evaluated in detail 44 confirmed fatal cases of HPS. Clinical and laboratory findings, diagnostic techniques together with autopsy pathologic data are described thoroughly. Furthermore, intriguing inferences are drawn between pathology and clinical course, providing a clue to the definition of HPS as a pulmonary capillary leak syndrome.
13. Nolte KB, Feddersen RM, Foucar K, Zaki SR, Koster FT, Madar M, McFeeley PJ, Umland ET, Zumwalt RE: Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Hum Pathol 1995, 26:110-120. This interesting article represents an important step in the understanding of HPS pathogenesis from a pathological point of view. Antemortem and postmortem pathological findings were evaluated in nine surviving and 13 dead patients. The authors confirm the lung as the primary target of the virus (capillary leak syndrome restricted to the pulmonary circulation) and HPS as a unique constellation of pulmonary, hematologic, and reticuloendotelial pathological abnormalities.
14. Ketai LH, Williamson MR, Telepak RJ, Levy H, Koster FT, Nolte KB, Allen SE: Hantavirus pulmonary syndrome: radiographic findings in 16 patients. Radiology 1995, 191:665-668. Excellent review of radiographic findings in HPS. The authors provide additional understanding to the pathogenesis of this atypical adult respiratory distress syndrome (mainly interstitial, with possible evolution to alveolar flooding with nonperipheral pattern). They further discuss the link among radiographic, clinical, and pathological findings, suggesting that the recognition of this unique radiographic pattern might be important in the differential diagnosis of adult respiratory distress syndrome.
15. Centers for Disease Control: Hantavirus pulmonary syndrome, 1993. MMWR Morb Mortal Wkly Rep 1993, 42:816-820.
16. Parmenter RR, Brunt JW, Moore DI: The hantavirus epidemic in the Southwest: rodent population dynamics and implications for transmission of hantavirus-associated adult respiratory distress syndrome (HARDS) in the Four Corners region. Sevilleta LTER Publication no. 41. Albuquerque, New Mexico: University of New Mexico; 1993.
17. Cook PJ, Honeyboume D: Chlamydia pneumoniae. J Antimicrob Chemother 1994, 34:859-873.
18. Grayston JT, Kuo CC, Campbell LA, Wang SP: Chlamydia pneumoniae sp. nov. for Chlamydia sp. strain TWAR. Int J Syst Bacteriol 1989, 39:88-90.
19. Falck G, Heyman L, Gnarpe J, Gnarpe H: Chlamydia pneumoniae (TWAR): a common agent in acute bronchitis. Scand J Infect Dis 1994, 26:179-187.
20. Blasi F, Legnani D, Lombarde VM, Negretto GG, Magliano E, Pozzoli R, Chiodo F, Fasoli A, Allegra L: Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993, 6:19-22.
21. von Hertzen L, Leinonen M, Koskinen R, Liipo K, Saikku P: Evidence of persistent Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease. In Proceedings of the Eighth International Symposium on Human Chlamydial infetion. Edited by Orfila J et al. Bologna: Società Editrice Esculapio; 1994:473-476.
22. Shemer-Avni Y, Lieberman D: Chlamydia pneumoniae-induced ciliostasis in ciliated bronchial epithelial cells. J Infect Dis 1995, 171:1274-1278. An excellent study on in vitro effects of chlamydial infection on ciliary motility of bronchial epithelial cells. The authors characterized the inhibitory effect of C. pneumoniae on the ciliary activity. They demonstrated that C. pneumoniae inhibition of the beating of ciliated bronchial epithelial cells was probably caused by the structural moiety of C. pneumoniae particles that exert a toxic effect. The results support the hypothesis that decrease of ciliary motility might be an important facilitating factor in C. pneumoniae respiratory infections. Moreover, toxic effects to epithelial cells may account for some of the clinical manifestation of acute C. pneumoniae infection or chronic infection, such as development of chronic bronchitis.
23. Maaertens G, Lewis SJ, de Goveia C, Bartie C, Roditi D, Klugman KP: 'Atypical' bacteria are common cause of community-acquired pneumonia in hospitalised adults. S Afr Med J 1994, 84:678-682.
24. Thom D, Grayston JT, Campbell LA, Kuo CC, Diwan VK, Wang SP: Respiratory infection with Chlamydia pneumoniae in middle-aged and older adult patients. Eur J Clin Microbiol Infect Dis 1994, 13:785-792.
25. Cosentini R, Blasi F, Raccanelli R, Rossi S, Arosio C, Tarsia P, Randazzo A, Allegra L: Severe community-acquired pneumonia: a possible role for Chlamydia pneumoniae. Respiration 1996, in press.
26. Denti F, Allegra L, Blasi F: Chlamydia pneumoniae pneumonia: radiological features. In Chlamydia pneumoniae infection. Edited by Allegra L, Blasi F. Milan: Springer-Verlag; 1995:76-81.
27. Aldous MB, Grayston JT, Wang SP, Foy HM: Seroepldemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966-1979. J Infect Dis 1992, 166:646-649.
28. Blasi F, Boschini A, Cosentini R, Legnani D, Ghira C, Smacchia C, Allegra L: Outbreak of Chlamydia pneumoniae infection in former injection-drug users. Chest 1994, 105:812-815.
29. Blasi F, Cosentini R, Denti F, Allegra L: Two family outbreaks of Chlamydia pneumoniae infection. Eur Respir J 1994, 7:102-104.
30. Jantos CA, Wienpahl B, Schiefer HG, Wagner F, Hegemann JH: Infection with Chlamydia pneumoniae in infants and children with acute lower respiratory tract disease. Pediatr Infect Dis J 1995, 14:117-122.
31. Thom D: Lower respiratory tract Infection with Chlamydia pneumoniae. Arch Fam Med 1994, 3:828-832.
32. Saikku P, Ruutu P, Leinonen M, Panelius J, Tupasi TE, Grayston JT: Acute lower-respiratory tract Infection associated with chlamydial TWAR antibody in Filipino children. J Infect Dis 1988, 158:1095-1097.
33. Forgie IM, O'Neil KP, Lloyd-Evans N, Leinonen M, Campbell H, Whittle HC, Greenwood BM: Etiology of acute lower respiratory tract infections in Gambian children, II: acute lower respiratory tract infection in children aged one to nine years presenting at the hospital. Pediatr Infect Dis J 1991, 10:42-47.
34. Augenbraun MH, Roblin MR, Chirwing K, Landman D, Hammerschlag MR: Isolation of Chlamydia pneumoniae from lungs of patients infected with the human immonodeficiency virus. J Clin Microbiol 1991, 29:401-402.
35. Clark R, Mushatt D, Fazal B: Case report: Chlamydia pneumoniae pneumonia in an HIV-infected man. Am J Med Sci 1991, 302:155-156.
36. Blasi F, Cosentini R, Clerici Shoeller M, Lupo A, Allegra L: Chlamydia pneumoniae seroprevalence in immunocompetent and immunocompromised populations in Milan. Thorax 1993, 48:1261-1263.
37. Dalhoff K, Maass M, Kamp S, Braun J, Wiebmann KJ: Clinical features of BAL-confirmed Chlamydia pneumoniae infection in immunocompetent and immunocompromised patients [abstract]. Eur Respir J 1995; 8(suppl 19):6S.
38. Hahn DL, Dodge RW, Golubjatnikov R: Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA 1991, 266:225-230.
39. Emre U, Roblin PM, Gelling M, Dumomay W, Rao M, Hammerschlag MR, Schacter J: The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med 1994, 148:727-732.
40. Emre U, Sokolovskaia N, Roblin PM, Schachter J, Hammerschlag MR: Detection of anti-Chlamydia pneumoniae IgE in children with reactive airway disease. J Infect Dis 1995, 172:265-267.
41. Grayston JT, Campbell LA, Kuo CC, Mordhorst CH, Saikku P, Thom DH, Wang SP: A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990, 161:618-625.
42. Maass M, Harig U: Evaluation of culture conditions used for isolation of Chlamydia pneumoniae. Am J Clin Pathol 1995, 103:141-148.
43. Gaydos CA, Quinn TC, Eiden JJ: Identification of Chlamydia pneumoniae by DNA amplification of the 16S rRNA gene. J Clin Microbiol 1992, 30:796-800.
44. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT: Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993, 167:841-849.
45. Campbell LA, Melgosa MP, Hamilton DJ, Kuo CC, Grayston JT: Detection of Chlamydia pneumoniae by polymerase chain reaction. J Clin Microbiol 1992, 30:434-439.
46. Tong CYW, Sillis M: Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR. J Clin Pathol 1993, 46:313-317.
47. Maass M, Dalhoff K: Comparison of sample preparation methods for detection of Chlamydia pneumoniae in bronchoalveolar lavage fluid by PCR. J Clin Microbiol 1994, 32:2616-2619.
48. Black CM, Fields PI, Messmer TO, Berdal BP: Detection of Chlamydia pneumoniae in clinical specimens by polymerase chain reaction using nested primers. Eur J Clin Microbiol Infect Dis 1994, 13:752-756.
49. Prückl PM, Aspock C, Makristathis A, Rotter ML, Wank H, Willinger B, Hirschl AM: Polymerase chain reaction for detection of Chlamydia pneumoniae in gargled-water specimens of children. Eur J Clin Microbiol Infect Dis 1995, 14:141-143.
50. Cunningham A, Johnston S, Julious S, Sillis M, Ward ME: The role of Chlamydia pneumoniae and other pathogens in acute episodes of asthma in children. In Proceedings of the Eighth International Symposium on Human Chlamydial Infection. Edited by Orfila J, Byrne GI, et al. Bologna: Società Editrice Esculapio; 1994, 480-483.
51. Saikku P: Chronic Chlamydia pneumoniae infection. In Chlamydia pneumoniae Infection. Edited by Allegra L, Blasi F. Milan: Springer-Verlag; 1995:51-64. Excellent review of C. pneumoniae chronic infections. The author discusses the diagnostic methods for C. pneumoniae chronic infection and the diseases associated to this pathogen. Asthma and chronic cardiovascular diseases are the principal topics of the chapter. C. pneumonias is indicated as a possible cofactor in asthma and atherosclerosis etiopathogenesis.
52. Rizzato G, Montemurro L, Fraioli P, Montanari G, Fanti D, Pozzoli R, Magliano E: Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur Respir J 1995, 8:398-402.
53. Blasi F, Cosentini R, Tarsia P, Camusso L, Campi E, Allegra L: Chlamydia pneumoniae pneumonia: role of new macrolides. J Chemother 1995, 7(suppl 4):117-118.
54. Pennington JE: Community-acquired pneumonia and acute bronchitis. In Respiratory Infection: Diagnosis & Management. Edited by Pennington JE. New York: Raven Press; 1994:193-206.
55. Macfarlane JT, Finch RG, Ward MJ, and Macrae AD: Hospital study of adult community-acquired pneumonia. Lancet 1982, 2:255-228.
56. Pareja A, Bernai C, Leyva A, Piedrola G, Maroto MC: Etiologic study of patients with community-acquired pneumonia. Chest 1992, 101:1207-1210.
57. Blasi F, Cosentini R, Legnani D, Denti F, Allegra L: Incidence of community-acquired pneumonia caused by Chlamydia pneumonias in Italian patients. Eur J Clin Microbiol Infect Dis 1993, 12:696-699.
58. Pallares R, Liñares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, Martin R, Guidol F: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995, 333:474-480. An excellent 10-year prospective study on the effects of S. pneumonias drug resistance on mortality. Among 504 patients, the authors found 29% and 6% penicillin- and cephalosporin-resistant strains, respectively. Interestingly, after adjusting for other predictors of mortality, the odds ratio for mortality in patients with penicillin-resistant strains was 1. Furthermore, in patients with penicillin and cephalosporin-resistant strains treated with penicillin and cephalosporin the mortality was not significantly different in comparison with patients with sensitive strains. The authors conclude that penicillins and cephalosporins remain the treatment of choice for severe pneumococcal pneumonia.
59. Hansman D, Bullen MM: A resistant pneumococcus. Lancet 1967, 2:264-265.
60. Goldstein FW, Garau J: Resistant pneumococcl: a renewed threat in respiratory infections. Scand J Infect Dis 1994, 93(supp):55-62.
61. Lonks RJ, Medeiros AA: The growing threat of antibiotic-resistant Streptococcus pneumonias. Med Clin North Am 1995, 79:523-535. An extremely detailed review on Streptococcus pneumoniae antibiotic resistance. Interestingly, the authors report an increasing rate of erythromycin resistance (6% in United States during 1992) and the appearance of multiple drug-resistant strains, occurring in only four capsular types (6B, 14, 19A, and 23F). Risk factors seem to be advanced age, prior use of antibiotics, and hospitalization. Finally, they emphasize the need to develop a better vaccine for the primary prevention of pneumococal disease.
62. Lee HJ, Park JY, Jang SH, Kim JH, Kim EC, Choi KW: High Incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumonias from a university hospital in Korea. Clin Infect Dis 1995, 20:826-835.
63. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard.NCCLS document M7-A3, edn. 3. Villanova, PA: NCCLS; 1993.
64. Joegensen JH, Ferraro MJ, McElmeel ML, Spargo J, Swenson JM, Tenover FC: Detection of penicillin and extended-spectrum cephalosporin resistance among Streptococcus pneumoniae clinical isolates by use of the E test. J Clin Microbiol 1994, 32:159-163.
65. Krisher KK, Linscott A: Comparison of three commercial MIC systems, E test. Fastidious Antimicrobial Susceptibility panel, and Fox fastidious panel, for confirmation of penicillin and cephalosporin resistance in Streptococcus pneumoniae. J Clin Microbiol 1994, 32:2242-2245.
66. Friedland IR, McCracken GH Jr: Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994, 331:377-382.
67. Austrian R: Confronting drug-resistant pneumococci. Ann Intern Med 1994, 121:807-809. After an excellent descriptive narrative on pneumococcal resistance history, the author discusses its genetic mechanisms and geographic spread. Therapeutic management is illustrated, in which high-dose penicillin (1,200,000 U/2 hours), ceftriaxone, or vancomycin are suggested, remembering the penicillin's inability to reach adequate levels in the subarachnoid space. Interestingly, the author suggests to immunize all adults, thereby reducing the incidence of potentially fatal infections and the pneumococcal carrier rate in the general population.
68. Guerra LG, Verghese A: New pathogens in pneumonia. Med Clin North Am 1994, 78:967-985.
69. Marrie TJ: New aspects of old pathogens of pneumonia. Med Clin North Am 1994, 78:987-995.